Applications of the ddRNAi technology for research activities have been licensed exclusively by Sigma- Aldrich from Benitec Limited of Australia. Financial details of the deal were not disclosed.
According to Sigma-Aldrich, the use of ddRNAi to develop therapeutics is recognized as having a number of critical advantages available over alternative RNAi and other gene silencing technologies. These include the wide range of technologies to deliver the ddRNAi molecules into the target cell and the ability to control the expression and timing of gene silencing, particularly important to the development of drugs for the pharmaceutical industry.